Yutaka Fujiwara

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 22

Top Venues

Cancer science

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer medicine

Respirology case reports

Mitsui Memorial Hospital

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Mitsui Memorial Hospital Jan 01 2019

Japan

Head :: Respiratory Medicine

Publications

Yutaka Fujiwara, Reiko Makihara, Tetsunari Hase, Naozumi Hashimoto, Tomoyuki Naito, Yukari Tsubata, Takae Okuno, Toshiaki Takahashi, Haruki Kobayashi, Yuki Shinno, Yoshitaka Zenke, Takaya Ikeda, Yukio Hosomi, Kageaki Watanabe, Satoru Kitazono, Naomi Sakiyama, Yoshinori Makino, Noboru Yamamoto
Pharmacokinetic and dose-finding study of osimertinib in patients with impaired renal function and low body weight. Cancer science (2023)
Yutaka Fujiwara, Yasuo Takahashi, Morihito Okada, Takumi Kishimoto, Shunsuke Kondo, Koshi Fujikawa, Manabu Hayama, Masatoshi Sugeno, Shinya Ueda, Keiko Komuro, Mark Lanasa, Takashi Nakano
Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma. The oncologist 27 (9) (2022)
Yoshitsugu Horio, Hiroyuki Tachibana, Junichi Shimizu, Waki Hosoda, Yutaka Fujiwara
Successful IMRT and concurrent chemotherapy for a patient with intrathoracic extensive-stage small cell lung cancer. Respirology case reports 10 (4) (2022)
Jun Sato, Toshio Shimizu, Takafumi Koyama, Satoru Iwasa, Akihiko Shimomura, Shunsuke Kondo, Shigehisa Kitano, Kan Yonemori, Yutaka Fujiwara, Kenji Tamura, Takuya Suzuki, Takao Takase, Reiko Nagai, Kohei Yamaguchi, Taro Semba, Zi-Ming Zhao, Min Ren, Noboru Yamamoto
Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (9) (2022)
Satoru Iwasa, Takafumi Koyama, Makoto Nishino, Shunsuke Kondo, Kazuki Sudo, Kan Yonemori, Tatsuya Yoshida, Kenji Tamura, Toshio Shimizu, Yutaka Fujiwara, Shigehisa Kitano, Akihiko Shimomura, Jun Sato, Fumiharu Yokoyama, Hiroyuki Iida, Maki Kondo, Noboru Yamamoto
First-in-human study of ONO-4578, an antagonist of prostaglandin E 2 receptor 4, alone and with nivolumab in solid tumors. Cancer science (2022)
Masafumi Sata, Shinichi Sasaki, Katsunori Oikado, Yoshinobu Saito, Junya Tominaga, Fumikazu Sakai, Terufumi Kato, Tae Iwasawa, Hirotsugu Kenmotsu, Masahiko Kusumoto, Tomohisa Baba, Masahiro Endo, Yutaka Fujiwara, Hiroaki Sugiura, Noriyo Yanagawa, Yoshihiko Ito, Takahiko Sakamoto, Yuichiro Ohe, Kazuyoshi Kuwano
Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer. Cancer science 112 (4) (2021)
Shunji Takahashi, Yutaka Fujiwara, Kenji Nakano, Toshio Shimizu, Junichi Tomomatsu, Takafumi Koyama, Mariko Ogura, Masaya Tachibana, Yasuyuki Kakurai, Tomonari Yamashita, Sakura Sakajiri, Noboru Yamamoto
Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study. Cancer science 112 (6) (2021)
Mao Okumura, Eiji Nakano, Kenjiro Namikawa, Akira Takahashi, Yutaka Fujiwara, Naoya Yamazaki
Efficacy of surgery for skin cancers initially suspected to be carcinoma of unknown primary: a retrospective observational study. International journal of dermatology (2021)
Toshio Shimizu, Yutaka Fujiwara, Kan Yonemori, Takafumi Koyama, Jun Sato, Kenji Tamura, Akihiko Shimomura, Hiroki Ikezawa, Maiko Nomoto, Keiji Furuuchi, Ryo Nakajima, Takuma Miura, Noboru Yamamoto
First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (14) (2021)
Yutaka Fujiwara, Aya Kuchiba, Takafumi Koyama, Ryunosuke Machida, Akihiko Shimomura, Shigehisa Kitano, Toshio Shimizu, Noboru Yamamoto
Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials. ESMO open 5 (2) (2021)
Shunsuke Kondo, Toshio Shimizu, Takafumi Koyama, Jun Sato, Satoru Iwasa, Kan Yonemori, Yutaka Fujiwara, Akihiko Shimomura, Shigehisa Kitano, Kenji Tamura, Noboru Yamamoto
First-in-human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors. Cancer science 112 (4) (2021)
Yoshinobu Saito, Shinichi Sasaki, Katsunori Oikado, Junya Tominaga, Masafumi Sata, Fumikazu Sakai, Terufumi Kato, Tae Iwasawa, Hirotsugu Kenmotsu, Masahiko Kusumoto, Tomohisa Baba, Masahiro Endo, Yutaka Fujiwara, Hiroaki Sugiura, Noriyo Yanagawa, Yoshihiko Ito, Takahiko Sakamoto, Yuichiro Ohe, Kazuyoshi Kuwano
Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer. Cancer science 112 (4) (2021)
Yutaka Fujiwara, Hirotsugu Kenmotsu, Noboru Yamamoto, Toshio Shimizu, Kan Yonemori, Christopher Ocampo, Apurvasena Parikh, Sumiko Okubo, Kazuteru Fukasawa, Haruyasu Murakami
Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors. Cancer medicine 10 (7) (2021)
Yusuke Okuma, Yasushi Goto, Fumiyoshi Ohyanagi, Kuniko Sunami, Yoshiro Nakahara, Satoru Kitazono, Keita Kudo, Yuichi Tambo, Shintaro Kanda, Noriko Yanagitani, Atsushi Horiike, Hidehito Horinouchi, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Makoto Nishio, Yuichiro Ohe, Yukio Hosomi
Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma. Cancer medicine 9 (20) (2020)
Shintaro Kanda, Yuichiro Ohe, Yasushi Goto, Hidehito Horinouchi, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Takanori Yamamoto, Tomohide Tamura
Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer. Cancer science 111 (6) (2020)
Takafumi Koyama, Toshio Shimizu, Satoru Iwasa, Yutaka Fujiwara, Shunsuke Kondo, Shigehisa Kitano, Kan Yonemori, Akihiko Shimomura, Sakura Iizumi, Tatsuya Sasaki, Junji Furuse, Noboru Yamamoto
First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. Cancer science 111 (2) (2020)
Yoshinori Makino, Reiko Makihara-Ando, Takanori Ogawa, Hitoshi Sato, Yasushi Goto, Shintaro Kanda, Hidehito Horinouchi, Yutaka Fujiwara, Yuichiro Ohe, Noboru Yamamoto
Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer. Cancer science 110 (11) (2019)
Akihiko Shimomura, Noboru Yamamoto, Shunsuke Kondo, Yutaka Fujiwara, Shigenobu Suzuki, Noriko Yanagitani, Atsushi Horiike, Satoru Kitazono, Fumiyoshi Ohyanagi, Toshihiko Doi, Yasutoshi Kuboki, Akihito Kawazoe, Kohei Shitara, Izumi Ohno, Udai Banerji, Raghav Sundar, Shuichi Ohkubo, Elizabeth M Calleja, Makoto Nishio
First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors. Molecular cancer therapeutics 18 (3) (2019)
Hirotsugu Kenmotsu, Kiyotaka Yoh, Keita Mori, Akira Ono, Tomohisa Baba, Yutaka Fujiwara, Ou Yamaguchi, Ryo Ko, Hiroaki Okamoto, Nobuyuki Yamamoto, Takashi Ninomiya, Takashi Ogura, Terufumi Kato
Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease. Cancer science 110 (12) (2019)
Keiko Goto, Yutaka Fujiwara, Takeshi Isobe, Naoko Chayahara, Naomi Kiyota, Toru Mukohara, Yukari Tsubata, Takamasa Hotta, Kenji Tamura, Noboru Yamamoto, Hironobu Minami
Pharmacokinetic study of the oral fluorouracil antitumor agent S-1 in patients with impaired renal function. Cancer science 110 (6) (2019)
Shiro Kimbara, Yutaka Fujiwara, Shintaro Iwama, Ken Ohashi, Aya Kuchiba, Hiroshi Arima, Naoya Yamazaki, Shigehisa Kitano, Noboru Yamamoto, Yuichiro Ohe
Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer science 109 (11) (2018)
Kazushi Yoshida, Yutaka Fujiwara, Yasushi Goto, Takashi Kohno, Akihiko Yoshida, Koji Tsuta, Yuichiro Ohe
The first case of SMARCB1 (INI1) - deficient squamous cell carcinoma of the pleura: a case report. BMC cancer 18 (1) (2018)

Yutaka Fujiwara.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yutaka Fujiwara